Can J Gastroenterol Hepatol. 2014 Jun;28(6):305-10. doi: 10.1155/2014/892084.
Alaska Native persons experience gastric cancer incidence and mortality rates that are three to four times higher than in the general United States population.
To evaluate pepsinogen I, pepsinogen I/II ratio, anti-Helicobacter pylori and cytotoxin-associated gene A (CagA) antibody levels, and blood group for their associations with gastric cancer development in Alaska Native people.
The present analysis was a retrospective case-control study that matched gastric cancers reported to the Alaska Native Tumor Registry from 1969 to 2008 to three controls on known demographic risk factors for H pylori infection, using sera from the Alaska Area Specimen Bank. Conditional logistic regression evaluated associations between serum markers and gastric cancer.
A total of 122 gastric cancer cases were included, with sera predating cancer diagnosis (mean = 13 years) and 346 matched controls. One hundred twelve cases (91.8%) and 285 controls (82.4%) had evidence of previous or ongoing H pylori infection as measured by anti-H pylori antibody levels. Gastric cancer cases had a 2.63-fold increased odds of having positive anti-H pylori antibodies compared with their matched controls (P=0.01). In a multivariate model, noncardia gastric cancer (n=94) was associated with anti-H pylori antibodies (adjusted OR 3.92; P=0.004) and low pepsinogen I level (adjusted OR 6.04; P=0.04). No association between gastric cancer and blood group, anti-CagA antibodies or pepsinogen I/II ratio was found.
Alaska Native people with gastric cancer had increased odds of previous H pylori infection. Low pepsinogen I level may function as a precancer marker for noncardia cancer.
阿拉斯加原住民的胃癌发病率和死亡率比美国普通人群高出三到四倍。
评估胃蛋白酶原 I、胃蛋白酶原 I/II 比值、抗幽门螺杆菌和细胞毒素相关基因 A (CagA) 抗体水平以及血型与阿拉斯加原住民胃癌发展的关系。
本分析是一项回顾性病例对照研究,使用来自阿拉斯加地区标本库的血清,根据已知的幽门螺杆菌感染的人口统计学危险因素,将 1969 年至 2008 年向阿拉斯加原住民肿瘤登记处报告的胃癌病例与三名对照进行匹配。条件逻辑回归评估了血清标志物与胃癌之间的关系。
共纳入 122 例胃癌病例,其血清标本均在癌症诊断前(平均=13 年)采集,且有 346 例匹配对照。112 例(91.8%)和 285 例(82.4%)对照的抗幽门螺杆菌抗体水平显示有既往或现症幽门螺杆菌感染。与匹配对照相比,胃癌病例的抗幽门螺杆菌抗体阳性的可能性增加了 2.63 倍(P=0.01)。在多变量模型中,非贲门胃癌(n=94)与抗幽门螺杆菌抗体(调整后的 OR 3.92;P=0.004)和低胃蛋白酶原 I 水平(调整后的 OR 6.04;P=0.04)相关。未发现胃癌与血型、抗 CagA 抗体或胃蛋白酶原 I/II 比值之间存在关联。
患有胃癌的阿拉斯加原住民人群既往感染幽门螺杆菌的可能性增加。低胃蛋白酶原 I 水平可能是贲门癌的癌前标志物。